Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials#China#Shanghai#ADC#Mabwell#CDH17
Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials
Mabwell has received IND clearance for its CDH17-targeting ADC 7MW4911 from China's NMPA, aiming for clinical studies in advancing gastrointestinal cancers.
third-news.com
October 14, 2025 at 12:12 PM
Loss of IKKα function shown to promote colorectal cancer liver metastasis by expanding a CDH17⁺/CLDN2⁺ epithelial subpopulation characterized by tight junction stabilization and collective migration. doi.org/10.1038/s414...
January 5, 2026 at 2:51 PM
Loss of IKKα function shown to promote colorectal cancer liver metastasis by expanding a CDH17⁺/CLDN2⁺ epithelial subpopulation characterized by tight junction stabilization and collective migration. doi.org/10.1038/s414...
Dr. Damian McGlothlin + @sundarraghav.bsky.social present a study of #gastriccancer #ASCO26: Tumors w/ high CDH17 tended to have a more “immune-cold” environment. This may hell explain why some tumors are harder to treat, pointing to CDH17 as potential target. @oncoalert.bsky.social
May 30, 2026 at 5:46 PM
Dr. Damian McGlothlin + @sundarraghav.bsky.social present a study of #gastriccancer #ASCO26: Tumors w/ high CDH17 tended to have a more “immune-cold” environment. This may hell explain why some tumors are harder to treat, pointing to CDH17 as potential target. @oncoalert.bsky.social
SOTIO has dosed the first patient in CADENCIA-01, a Phase 1/2 trial of SOT109, its CDH17-targeting antibody-drug conjugate for advanced colorectal cancer. SOT109 holds FDA Fast Track Designation.
SOTIO doses first patient in CDH17-targeting ADC trial for CRC
SOTIO Biotech has initiated its CADENCIA-01 Phase 1/2 trial of SOT109, the only CDH17-targeting ADC with FDA Fast Track Designation, in advanced
biotech.disruptsmedia.com
September 10, 2026 at 10:42 AM
SOTIO has dosed the first patient in CADENCIA-01, a Phase 1/2 trial of SOT109, its CDH17-targeting antibody-drug conjugate for advanced colorectal cancer. SOT109 holds FDA Fast Track Designation.
Online now: Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor Online now:
Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor
Wang et al. develop 7MW4911, a CDH17-targeted ADC carrying a Top1 inhibitor MF-6. 7MW4911 shows strong anti-tumor activity in diverse GI cancer models, including MDR tumors, and demonstrates a favorable safety profile in monkeys, supporting its potential for overcoming drug resistance and advancing to clinical development.
dlvr.it
July 2, 2025 at 12:28 PM
Online now: Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor Online now:
The authors included RRIDs in their None paper! Thanks for making your methods matter! #accelerateopenscience #reproducibility #STMpublishing
Development and Preclinical Evaluation of CDH17-Specific ImmunoPET Imaging in Colorectal Cancers
doi.org
August 16, 2025 at 7:00 AM
The authors included RRIDs in their None paper! Thanks for making your methods matter! #accelerateopenscience #reproducibility #STMpublishing
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
August 28, 2026 at 1:37 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics
Intriguing results here, it gives this skeptic a little bit of hope for CAR-T in CRC.
Similar to Claudin 18.2, CDH17 is normally tucked away from the immune system in cell-cell junctions but exposed on the cell surface in tumors, making it a drug target- but one that spares normal tissue.
Similar to Claudin 18.2, CDH17 is normally tucked away from the immune system in cell-cell junctions but exposed on the cell surface in tumors, making it a drug target- but one that spares normal tissue.
Systemic delivery of cadherin 17–specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases | Science Translational Medicine www.science.org/doi/10.1126/... 🧪
Systemic delivery of cadherin 17–specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases
Systemic cadherin-17–specific CAR T cell therapy is efficacious against colorectal cancer liver metastases in multiple preclinical models.
www.science.org
May 29, 2025 at 11:24 AM
Intriguing results here, it gives this skeptic a little bit of hope for CAR-T in CRC.
Similar to Claudin 18.2, CDH17 is normally tucked away from the immune system in cell-cell junctions but exposed on the cell surface in tumors, making it a drug target- but one that spares normal tissue.
Similar to Claudin 18.2, CDH17 is normally tucked away from the immune system in cell-cell junctions but exposed on the cell surface in tumors, making it a drug target- but one that spares normal tissue.
RRIDs were included in this in Advanced Science paper. RRIDs improve reproducibility in scientific research. #methodsmatter #STMpublishing #OpenScience
Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers
Read the full paper: Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers
doi.org
September 16, 2026 at 7:35 PM
RRIDs were included in this in Advanced Science paper. RRIDs improve reproducibility in scientific research. #methodsmatter #STMpublishing #OpenScience
#AVBP ArriVent BioPharma Reports Second Quarter 2026 Financial Results
https://www.stocktitan.net/news/AVBP/arri-vent-bio-pharma-reports-second-quarter-2026-financial-hdz6znbv57ut.html
https://www.stocktitan.net/news/AVBP/arri-vent-bio-pharma-reports-second-quarter-2026-financial-hdz6znbv57ut.html
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b
www.stocktitan.net
August 12, 2026 at 8:01 PM
#AVBP ArriVent BioPharma Reports Second Quarter 2026 Financial Results
https://www.stocktitan.net/news/AVBP/arri-vent-bio-pharma-reports-second-quarter-2026-financial-hdz6znbv57ut.html
https://www.stocktitan.net/news/AVBP/arri-vent-bio-pharma-reports-second-quarter-2026-financial-hdz6znbv57ut.html
CDH17 is an emerging therapeutic target for gastrointestinal cancers. This study reports the development of two complementary CDH17-targeted modalities - an antibody - drug conjugate (ADC) and a γδ T cell engager - both demonstrating potent preclinical antitumor activity.
doi.org/10.1093/abt/...
doi.org/10.1093/abt/...
August 6, 2026 at 9:50 PM
CDH17 is an emerging therapeutic target for gastrointestinal cancers. This study reports the development of two complementary CDH17-targeted modalities - an antibody - drug conjugate (ADC) and a γδ T cell engager - both demonstrating potent preclinical antitumor activity.
doi.org/10.1093/abt/...
doi.org/10.1093/abt/...
Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Research Highlight - "Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers"
doi.org/10.1093/abt/...
#antibody #antibodydrugconjugate #tcellengager #gammadeltatcells #immunotherapy
doi.org/10.1093/abt/...
#antibody #antibodydrugconjugate #tcellengager #gammadeltatcells #immunotherapy
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers
Statement of Significance We developed two novel complementary therapeutic modalities targeting an emerging gastrointestinal tumor-associated antigen, CDH1
doi.org
August 6, 2026 at 9:49 PM
Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Research Highlight - "Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers"
doi.org/10.1093/abt/...
#antibody #antibodydrugconjugate #tcellengager #gammadeltatcells #immunotherapy
doi.org/10.1093/abt/...
#antibody #antibodydrugconjugate #tcellengager #gammadeltatcells #immunotherapy
🔬 Highlights:
• Engineered a CDH17-targeted γδ T cell engager capable of recruiting both Vδ1 and Vδ2 γδ T cells for tumor cell killing
• IL-15 fusion further enhanced γδ T cell expansion and activation, supporting combination immunotherapy strategies
doi.org/10.1093/abt/...
• Engineered a CDH17-targeted γδ T cell engager capable of recruiting both Vδ1 and Vδ2 γδ T cells for tumor cell killing
• IL-15 fusion further enhanced γδ T cell expansion and activation, supporting combination immunotherapy strategies
doi.org/10.1093/abt/...
August 6, 2026 at 9:51 PM
🔬 Highlights:
• Engineered a CDH17-targeted γδ T cell engager capable of recruiting both Vδ1 and Vδ2 γδ T cells for tumor cell killing
• IL-15 fusion further enhanced γδ T cell expansion and activation, supporting combination immunotherapy strategies
doi.org/10.1093/abt/...
• Engineered a CDH17-targeted γδ T cell engager capable of recruiting both Vδ1 and Vδ2 γδ T cells for tumor cell killing
• IL-15 fusion further enhanced γδ T cell expansion and activation, supporting combination immunotherapy strategies
doi.org/10.1093/abt/...
🧬🚀 The FDA has granted Fast Track designation to SOT109, an investigational CDH17-targeted antibody-drug conjugate for patients with advanced colorectal cancer.
Read more ➡️ www.onclive.com/view/fda-gra...
#ColorectalCancer #CRC #GIonc #ADC #TargetedTherapy #ClinicalTrials #Oncology
Read more ➡️ www.onclive.com/view/fda-gra...
#ColorectalCancer #CRC #GIonc #ADC #TargetedTherapy #ClinicalTrials #Oncology
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer | OncLive
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
www.onclive.com
July 14, 2026 at 3:41 PM
🧬🚀 The FDA has granted Fast Track designation to SOT109, an investigational CDH17-targeted antibody-drug conjugate for patients with advanced colorectal cancer.
Read more ➡️ www.onclive.com/view/fda-gra...
#ColorectalCancer #CRC #GIonc #ADC #TargetedTherapy #ClinicalTrials #Oncology
Read more ➡️ www.onclive.com/view/fda-gra...
#ColorectalCancer #CRC #GIonc #ADC #TargetedTherapy #ClinicalTrials #Oncology
Tight Junction-high and CDH17-positive cell population is the Source of Colorectal Cancer Liver Metastases #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-6998644/latest
https://www.researchsquare.com/article/rs-6998644/latest
July 9, 2025 at 4:00 PM
Tight Junction-high and CDH17-positive cell population is the Source of Colorectal Cancer Liver Metastases #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-6998644/latest
https://www.researchsquare.com/article/rs-6998644/latest
[1/2] 2026-05-07 08:44:36 - [InnoCare: CDH17-targeting ADC innovative drug ICP-B208 has been approved for clinical trials] On May 7, InnoCare announced that the company’s independently developed new ADC innovative drug ICP-B208, targeting CDH17, was approved by the Center for Drug
May 7, 2026 at 12:50 AM
[1/2] 2026-05-07 08:44:36 - [InnoCare: CDH17-targeting ADC innovative drug ICP-B208 has been approved for clinical trials] On May 7, InnoCare announced that the company’s independently developed new ADC innovative drug ICP-B208, targeting CDH17, was approved by the Center for Drug
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. aacrjournals.org/cancerrescom... #hvhebron #onco [Text complet]
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
Abstract. Purpose: BI 905711, a TRAILR2/CDH17 bispecific antibody, demonstrated preclinical apoptotic pathway activation and antitumor activity. Two phase Ia/Ib studies tested BI 905711 monotherapy (N...
aacrjournals.org
April 27, 2026 at 10:12 AM
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. aacrjournals.org/cancerrescom... #hvhebron #onco [Text complet]
Chimeric Therapeutics ( #CHM ) has released " $8.4 M funding to drive CHM CDH17 and resignation of CMO " on Tue 23 Dec at 09:53 AEST #trading #Mining #UnitedStates #ClinicalTrials #Australia
Grafa
Grafa is the world's most powerful AI market screener for shares, crypto and forex. Track the ASX200, Dow Jones, NYSE, Nasdaq, crypto, and company share prices. Research finance terms and uncover hot stocks
grafa.com
December 22, 2025 at 10:59 PM
Chimeric Therapeutics ( #CHM ) has released " $8.4 M funding to drive CHM CDH17 and resignation of CMO " on Tue 23 Dec at 09:53 AEST #trading #Mining #UnitedStates #ClinicalTrials #Australia
Chimeric Therapeutics ( #CHM ) has released " CHM CDH17 receives FDA Fast Track " on Wed 04 Jun at 09:47 AEST #ClinicalTrials #Australia #media #ASX #gas
Chimeric Therapeutics share price
Chimeric Therapeutics (ASX:CHM) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Chimeric Therapeutics’s share price,
grafa.com
June 3, 2025 at 11:53 PM
Chimeric Therapeutics ( #CHM ) has released " CHM CDH17 receives FDA Fast Track " on Wed 04 Jun at 09:47 AEST #ClinicalTrials #Australia #media #ASX #gas
Chimeric Therapeutics ( #CHM ) has released " CHM CDH17 ADVANCES TO DOSE LEVEL 2 " on Wed 21 May at 09:38 AEST #ClinicalTrials #Australia #media #live #ASX
Chimeric Therapeutics share price
Chimeric Therapeutics (ASX:CHM) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Chimeric Therapeutics’s share price,
grafa.com
May 20, 2025 at 11:43 PM
Chimeric Therapeutics ( #CHM ) has released " CHM CDH17 ADVANCES TO DOSE LEVEL 2 " on Wed 21 May at 09:38 AEST #ClinicalTrials #Australia #media #live #ASX
Feed: "Endpoints News"
By: Ayisha Sharma on Friday, October 17, 2025
By: Ayisha Sharma on Friday, October 17, 2025
Roche inks $80M upfront deal for Hansoh’s cancer ADC
Roche pays $80M upfront for Hansoh's ADC cancer drug HS-20110, excluding China rights. Deal includes $1.45B in milestones. Drug targets CDH17 protein in colorectal cancer.
endpoints.news
October 17, 2025 at 8:13 PM
Feed: "Endpoints News"
By: Ayisha Sharma on Friday, October 17, 2025
By: Ayisha Sharma on Friday, October 17, 2025
Feed: "Small Caps"
By: Imelda Cotton on Wednesday, June 4, 2025
By: Imelda Cotton on Wednesday, June 4, 2025
Chimeric Therapeutics gains FDA fast-track approval for CHM CDH17 gastrointestinal cancer candidate
Chimeric Therapeutics (ASX: CHM) has received fast-track designation from the US Food and Drug Administration (FDA) for lead candidate CHM CDH17 to treat
smallcaps.com.au
June 4, 2025 at 11:15 AM
Feed: "Small Caps"
By: Imelda Cotton on Wednesday, June 4, 2025
By: Imelda Cotton on Wednesday, June 4, 2025
CDH6, CDH17, CDH3 — from EMT textbooks to clinical-stage ADC programs in just a few years.
Translation is accelerating.
But the foundational question remains:
How is your target expressed in real patient tissue?
IHC still provides the answer.
We develop validated antibodies to support that work.👇
Translation is accelerating.
But the foundational question remains:
How is your target expressed in real patient tissue?
IHC still provides the answer.
We develop validated antibodies to support that work.👇
March 3, 2026 at 10:52 AM
CDH6, CDH17, CDH3 — from EMT textbooks to clinical-stage ADC programs in just a few years.
Translation is accelerating.
But the foundational question remains:
How is your target expressed in real patient tissue?
IHC still provides the answer.
We develop validated antibodies to support that work.👇
Translation is accelerating.
But the foundational question remains:
How is your target expressed in real patient tissue?
IHC still provides the answer.
We develop validated antibodies to support that work.👇
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs - BioWorld MedTech: Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs BioWorld MedTech
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs - BioWorld MedTech
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs BioWorld MedTech
news.google.com
December 13, 2025 at 12:00 AM
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs - BioWorld MedTech: Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs BioWorld MedTech